NovImmune SA is excited to be launching today the all new company website and branding.
Following the successful divestment of EmaCo AG, a newly established company owning emapalumab and related assets to Sobi on 18 July 2019, NovImmune underwent major rebranding activities.
NovImmune SA will continue the successful legacy of 20+ years of antibody expertise and focus on its bispecific technology and associated programs and will rebrand as:
«Light Chain Bioscience – A brand of Novimmune SA»
The brand Light Chain Bioscience brings to life the research and development of novel multi-specific antibodies that rely on their light chain for their function.
A key distinctive feature of these multispecific antibodies is their native human structure, making them well tolerated and easy to develop.
The rebranded website is live as of today and can be reached at www.lightchainbio.com
For more information please contact us via the contact form or via email:
